Eagle Health Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Eagle Health Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.6M	Buy	505,809 +138,997	+38%	+$8.1M	5%	6
2025 Q4	$21.8M	Hold	366,812	–	–	4.79%	8
2025 Q3	$19.9M	Hold	366,812	–	–	5.22%	8
2025 Q2	$20.2M	Sell	366,812 -15,800	-4%	-$930K	4.98%	9
2025 Q1	$27M	Sell	382,612 -36,600	-9%	-$2.46M	7.02%	6
2024 Q4	$27.6M	Hold	419,212	–	–	6.76%	6
2024 Q3	$29.5M	Buy	419,212 +187,412	+81%	+$15.7M	5.58%	10
2024 Q2	$19.1M	Buy	+231,800	New	+$19.3M	3.35%	13

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eagle Health Investments's BMRN Position: Q1 2026 in Review

Eagle Health Investments increased its BioMarin Pharmaceuticals (BMRN) stake by 38% in Q1 2026, buying an estimated $8.1M and bringing the position to 505,809 shares worth $28.6M. The position accounts for 5% of the portfolio, ranked #6.

Eagle Health Investments first reported a position in BMRN in Q2 2024 and has held it in 8 quarters since. The position peaked at $29.5M in Q3 2024. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Eagle Health Investments held 505,809 shares of BioMarin Pharmaceuticals worth $28.6M as of Q1 2026.
Eagle Health Investments bought 138,997 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $8.1M.
BioMarin Pharmaceuticals made up 5% of Eagle Health Investments's portfolio in Q1 2026, its #6 holding.
Eagle Health Investments first reported a position in BioMarin Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Eagle Health Investments's BioMarin Pharmaceuticals position peaked at $29.5M in Q3 2024.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Eagle Health Investments's 13F filing for Q1 2026, filed 15 May 2026.